A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

izalontamab brengitecan (BL-B01D1) - Sichuan Biokin Pharmaceutical, BMS, Systimmune

Airuikai (glecirasib) - Jacobio Pharma

http://clinicaltrials.gov/ct2/show/NCT07827261

Sep 19, 2026